Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
December 12, 2021 09:05 ET
|
Sana Biotechnology, Inc
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional...
Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
November 08, 2021 16:05 ET
|
Sana Biotechnology, Inc
Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE...
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
November 04, 2021 09:07 ET
|
Sana Biotechnology, Inc
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
October 19, 2021 09:00 ET
|
Sana Biotechnology, Inc
Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and...
Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates
August 04, 2021 16:05 ET
|
Sana Biotechnology, Inc
Presented data showing immune evasion and survival after transplantation of allogeneic cells into primates without immune suppression at ISSCR 2021 Entered long-term lease to establish manufacturing...
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
July 14, 2021 16:10 ET
|
Sana Biotechnology, Inc
Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies Facility Able to Support Clinical Trial and Early Commercial Launches of Multiple Programs State-of-the-Art...
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
June 26, 2021 10:42 ET
|
Sana Biotechnology, Inc
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a...
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
June 14, 2021 09:15 ET
|
Sana Biotechnology, Inc
SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be...
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...